CGEN-327

CGEN-327 is a recombinant protein candidate discovered by Compugen Ltd. using its proprietary *in silico* discovery platform. It is a naturally occurring soluble splice variant of B7-H3 (CD276), a member of the B7 family of immune checkpoint molecules. While B7-H3 is frequently targeted in oncology to block its inhibitory effects on the immune system, CGEN-327 was developed as a therapeutic agonist to exploit these same inhibitory pathways for the treatment of autoimmune and inflammatory diseases. By binding to its receptor on T-cells, CGEN-327 suppresses T-cell proliferation and the production of pro-inflammatory cytokines, such as interferon-gamma and IL-2. Although preclinical studies demonstrated potential in models of Th1-mediated diseases like multiple sclerosis and rheumatoid arthritis, the program was eventually discontinued as the developer shifted focus toward its clinical-stage oncology pipeline targeting PVRIG and TIGIT.

Other names

Soluble B7-H3B7-H3 soluble variantB-7-H3 soluble variantB 7-H3 soluble variant